End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.67 MXN | +2.27% | +8.60% | +17.73% |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- With a P/E ratio at 13.18 for the current year and 7.6 for next year, earnings multiples are highly attractive compared with competitors.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.73% | 911M | B+ | ||
+29.68% | 699B | C+ | ||
+25.07% | 571B | B | ||
-4.35% | 364B | C+ | ||
+17.65% | 326B | B- | ||
+3.77% | 286B | C+ | ||
+14.68% | 236B | B+ | ||
+4.71% | 198B | B- | ||
-12.43% | 194B | A+ | ||
-3.79% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.